This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a non-randomised controlled trial that was carried out in a single centre. The patients were divided into two groups according to whether or not they had syringomyelia. Twelve patients with syringomyelia underwent a standard CCJ decompression and 12 patients without syringomyelia underwent a dura-splitting CCJ decompression. Blinding was not used in the study. The mean follow-up period was approximately 15 months in both groups.
Analysis of effectiveness
The primary health outcomes used were: the outcome score, ranging from -1 (poor outcome, all symptoms worsened) to 2 (good outcome, all symptoms resolved); blood loss; complications; and readmission.
It appears that the analysis of the clinical study has been conducted on the basis of treatment completers only. The groups were generally shown to be comparable in terms of their age, gender distributions, and presenting clinical symptoms. The exceptions were incidence of headache and incidence of scoliosis alone and urinary incontinence. Ttests were used to compare all quantitative data for each group.
Effectiveness results
The clinical outcome scores demonstrated that most major presenting symptoms improved or resolved in both groups.
The mean outcome score was 1.53 for duraplasty and 1.67 for dura-splitting. The difference was not statistically significant.
The anaesthesiologists' estimates of blood loss were no different between the groups. Mean blood loss was estimated to be 80 mL (range: 25 -250) for the duraplasty group and 73 mL (range: 25 -300) for the dura-splitting group. The difference was not statistically significant.
There were no cerebrospinal fluid (CSF)-related, or any other complications, among those who underwent durasplitting CCJ decompression.
One patient in the duraplasty group was readmitted to the hospital.
Clinical conclusions
Dura-splitting decompression for paediatric Chiari I malformation is better tolerated by the patients and avoids exposure to CSF-related complications compared with CCJ decompression and duraplasty.
Measure of benefits used in the economic analysis
No summary measure of benefits was used. The study was, in effect, a cost-consequences analysis.
Direct costs
The direct costs included the total hospital charges. Resource use quantities such as operative time, total operative room time and hospital length of stay were reported, but the unit costs were not. The estimations of the quantities and costs were based on actual data from the hospital database for the period between July 2000 and October 2002. The price year was not reported. Discounting was not performed, which was appropriate as the time horizon was less than 2 years.
